CARA Cara Therapeutics, Inc.: institutional ownership and insider trading
Over the last 12 months insiders bought $0 and sold $0 on the open market.
CARA revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$6.46M, EPS -0.69
- Quarter ended Mar 31, 2026: revenue n/a, net income −$6.80M, EPS -0.73
- Quarter ended Dec 31, 2025: revenue n/a, net income −$7.27M, EPS 2.05
- Quarter ended Sep 30, 2025: revenue n/a, net income −$5.53M, EPS -0.59
Recent CARA insider trades
- Feb 28, 2025: Posner Christopher sold 583 shares ($2.77K)
- Feb 28, 2025: Terrillion Scott sold 163 shares ($776)
- Feb 4, 2025: Posner Christopher sold 372 shares ($1.76K)
- Nov 4, 2024: Posner Christopher sold 3,668 shares ($1.06K)
5%+ owners
- Sporos Bioventures LLC: 9.0% (Schedule 13G, filed Aug 8, 2025)
- Solas Tvardi Sidecar LLC: 8.1% (Schedule 13G, filed Apr 22, 2025)
- Slate Path Capital LP: 7.5% (Schedule 13G, filed Aug 14, 2025)
- David J. Tweardy: 7.0% (Schedule 13G, filed May 2, 2025)
Are insiders buying or selling CARA?
No open-market insider buys or sells of Cara Therapeutics, Inc. were reported in the last 12 months.